Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search
  1. NCI-F Publications

Search
  1. Year Published:

Your search returned 143 results.
User Information
Export Records
  1. 1.   Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants
  2. Zhang, Ling; Norberg, Scott M; Karimipour, Farrah; Davies, John S; Kuznetsov, Alex; Lassoued, Wiem; Burnett, Daniel; Homan,Philip; Cam, Margaret; Sinkoe, Andrew; Xue, Ping; Gulley, James L; Hinrichs, Christian S
  3. Journal for Immunotherapy of Cancer. 2024, Nov 18; 12(11):
  1. 2.   Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers
  2. Lim, Wan Ching; Marques Da Costa, Maria Eugenia; Godefroy, Karine; Jacquet, Eric; Gragert, Loren; Rondof, Windy; Marchais, Antonin; Nhiri, Naima; Dalfovo, Davide; Viard,Mathias; Labaied, Nizar; Khan, Asif M; Dessen, Philippe; Romanel, Alessandro; Pasqualini, Claudia; Schleiermacher, Gudrun; Carrington,Mary; Zitvogel, Laurence; Scoazec, Jean-Yves; Geoerger, Birgit; Salmon, Jerome
  3. Frontiers in Immunology. 2024, Jan 22; 14: 1265469.
  1. 3.   NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
  2. Salomé, Bérengère; Sfakianos, John P; Ranti, Daniel; Daza, Jorge; Bieber, Christine; Charap, Andrew; Hammer, Christian; Banchereau, Romain; Farkas, Adam M; Ruan, Dan Fu; Izadmehr, Sudeh; Geanon, Daniel; Kelly, Geoffrey; de Real, Ronaldo M; Lee, Brian; Beaumont, Kristin G; Shroff, Sanjana; Wang, Yuanshuo A; Wang, Ying-Chih; Thin, Tin Htwe; Garcia-Barros, Monica; Hegewisch-Solloa, Everardo; Mace, Emily M; Wang, Li; O'Donnell, Timothy; Chowell, Diego; Fernandez-Rodriguez, Ruben; Skobe, Mihaela; Taylor, Nicole; Kim-Schulze, Seunghee; Sebra, Robert P; Palmer, Doug; Clancy-Thompson, Eleanor; Hammond, Scott; Kamphorst, Alice O; Malmberg, Karl-Johan; Marcenaro, Emanuela; Romero, Pedro; Brody, Rachel; Viard,Mathias; Yuki,Yuko; Martin,Pat; Carrington,Mary; Mehrazin, Reza; Wiklund, Peter; Mellman, Ira; Mariathasan, Sanjeev; Zhu, Jun; Galsky, Matthew D; Bhardwaj, Nina; Horowitz, Amir
  3. Cancer Cell. 2022, Sep 12; 40(9): 1027-1043.e9.
  1. 4.   A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
  2. Manzo, Julia; Puhalla, Shannon; Pahuja, Shalu; Ding, Fei; Lin, Yan; Appleman, Leonard; Tawbi, Hussein; Stoller, Ronald; Lee, James J; Diergaarde, Brenda; Kiesel, Brian F; Yu, Jing; Tan, Antoinette R; Belani, Chandra P; Chew, Helen; Garcia, Agustin A; Morgan, Robert J; Wahner Hendrickson, Andrea E; Visscher, Daniel W; Hurley, Rachel M; Kaufmann, Scott H; Swisher, Elizabeth M; Oesterreich, Steffi; Katz, Tiffany; Ji,Jay; Zhang, Yiping; Parchment, Ralph E; Chen, Alice; Duan, Wenrui; Giranda, Vincent; Shepherd, Stacie P; Ivy, S Percy; Chu, Edward; Beumer, Jan H
  3. Cancer Chemotherapy and Pharmacology. 2022, Apr 18; 89(5): 721-735.
  1. 5.   The mechanism driving a solid-solid phase transition in a biomacromolecular crystal
  2. Ramakrishnan, Saminathan; Stagno,Jason; Heinz,Will; Zuo, Xiaobing; Yu,Ping; Wang,Yun-Xing
  3. IUCrJ. 2021, Jul 01; 8(Pt 4): 655-664.
  1. 6.   Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis
  2. Nguyen, Phuong H.; Ramamoorthy, Ayyalusamy; Sahoo, Bikash R.; Zheng, Jie; Faller, Peter; Straub, John E.; Dominguez, Laura; Shea, Joan-Emma; Dokholyan, Nikolay; De Simone, Alfonso; Ma, Buyong; Nussinov,Ruth; Najafi, Saeed; Ngo, Son Tung; Loquet, Antoine; Chiricotto, Mara; Ganguly, Pritam; McCarty, James; Li, Mai Suan; Hall, Carol; Wang, Yiming; Miller, Yifat; Melchionna, Simone; Habenstein, Birgit; Timr, Stepan; Chen, Jiaxing; Hnath, Brianna; Strodel, Birgit; Kayed, Rakez; Lesne, Sylvain; Wei, Guanghong; Sterpone, Fabio; Doig, Andrew J.; Derreumaux, Philippe
  3. Chemical Reviews. 2021, Feb 24; 121(4): 2545-2647.
  1. 7.   Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
  2. Kalinsky, Kevin; Hong, Fangxin; McCourt, Carolyn K.; Sachdev, Jasgit C.; Mitchell, Edith P.; Zwiebel, James A.; Doyle, L. Austin; McShane, Lisa M.; Li, Shuli; Gray, Robert J.; Rubinstein, Larry V.; Patton, David; Williams,Mickey; Hamilton, Stanley R.; Conley, Barbara A.; O'Dwyer, Peter J.; Harris, Lyndsay N.; Arteaga, Carlos L.; Chen, Alice P.; Flaherty, Keith T.
  3. JAMA oncology. 2021, Feb 1; 7(2): 271-278.
  1. 8.   Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
  2. Salama, April K S; Li, Shuli; Macrae, Erin R; Park, Jong-In; Mitchell, Edith P; Zwiebel, James A; Chen, Helen X; Gray, Robert J; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams,Mickey; Hamilton, Stanley R; Armstrong, Deborah K; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020, NOV 20; 38(33): JCO2000762.
  1. 9.   Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
  2. Chae, Young K; Hong, Fangxin; Vaklavas, Christos; Cheng, Heather H; Hammerman, Peter; Mitchell, Edith P; Zwiebel, James A; Ivy, S Percy; Gray, Robert J; Li, Shuli; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams,Mickey; Hamilton, Stanley R; Mansfield, Aaron; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020, JUL 20; 38(21): 2407-+.
  1. 10.   PI3K inhibitors: review and new strategies
  2. Zhang,Mingzhen; Jang,Hyunbum; Nussinov,Ruth
  3. CHEMICAL SCIENCE. 2020, JUN 21; 11(23): 5855-5865.
  1. 11.   Application of Post Solid-Phase Oxime Ligation to Fine-Tune Peptide-Protein Interactions
  2. Zhao,Xue Zhi; Liu, Fa; Burke,Terrence
  3. Molecules (Basel, Switzerland). 2020, JUN; 25(12):
  1. 12.   LC-MS/MS assay coupled with carboxylic acid magnetic bead affinity capture to quantitatively measure cationic host defense peptides (HDPs) in complex matrices with application to preclinical pharmacokinetic studies
  2. O'Neill,Maura; Chan,King; Jaynes, Jesse M; Knotts, Zachary; Xu,Xia; Abisoye-Ogunniyan, Abisola; Guerin,Theresa; Schlomer,Jerome; Li, Dandan; Cary, Jeffrey W; Rajasekaran, Kanniah; Yates, Clayton; Kozlov,Serguei; Andresson,Thorkell; Rudloff, Udo
  3. Journal of pharmaceutical and biomedical analysis. 2020, Mar 20; 181: 113093.
  1. 13.   Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
  2. Azad, Nilofer S; Gray, Robert J; Overman, Michael J; Schoenfeld, Jonathan D; Mitchell, Edith P; Zwiebel, James A; Sharon, Elad; Streicher, Howard; Li, Shuli; McShane, Lisa M; Rubinstein, Larry; Patton, David R; Williams,Mickey; Coffey,Brent; Hamilton, Stanley R; Bahary, Nathan; Suga, J Marie; Hatoum, Hassan; Abrams, Jeffrey S; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
  3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020, JAN 20; 38(3): 214-+.
  1. 14.   Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies
  2. Puxeddu, Michela; Shen, Hongliang; Bai,Ruoli; Coluccia, Antonio; Nalli, Marianna; Mazzoccoli, Carmela; Da Pozzo, Eleonora; Cavallini, Chiara; Martini, Claudia; Orlando, Viviana; Biagioni, Stefano; Mazzoni, Cristina; Coluccia, Addolorata Maria Luce; Hamel,Ernest; Liu, Te; Silvestri, Romano; La Regina, Giuseppe
  3. European journal of medicinal chemistry. 2020, Jan 1; 185: 111828.
  1. 15.   Blood Interactions, Pharmacokinetics, and Depth-Dependent Ablation of Rat Mammary Tumors with Photoactivatable, Liposomal Doxorubicin
  2. Carter, Kevin A.; Luo, Dandan; Geng, Jumin; Stern, Steve; Lovell, Jonathan F.
  3. Molecular cancer therapeutics. 2019, Mar; 18(3): 592-601.
  1. 16.   NCI Program for Natural Product Discovery: A Publicly-Accessible Library of Natural Product Fractions for High-Throughput Screening
  2. Thornburg,Chris; Britt,John; Evans,Jason; Akee,Rhone; Whitt, James A.; Trinh,Spencer; Harris,Matthew; Thompson,Jerell; Ewing,Teresa; Shipley,Suzanne; Grothaus,Paul; Newman,Dave; Schneider,Joel; Grkovic,Tanja; O'Keefe,Barry
  3. ACS CHEMICAL BIOLOGY. 2018, Sep 21; 13(9): 2484-2497.
  1. 17.   Activity-Dependent Neuroplasticity Induced by an Enriched Environment Reverses Cognitive Deficits in Scribble Deficient Mouse
  2. Hilal, Muna L; Moreau, Maité M; Racca, Claudia; Pinheiro, Vera L; Piguel, Nicolas H; Santoni, Marie-Josée; Dos Santos Carvalho, Steve; Blanc, Jean-Michel; Abada, Yah-Se K; Peyroutou, Ronan; Medina, Chantal; Doat, Hélène; Papouin, Thomas; Vuillard, Laurent; Borg, Jean-Paul; Rachel, Rivka; Panatier, Aude; Montcouquiol, Mireille; Oliet, Stéphane H R; Sans, Nathalie
  3. Cerebral cortex (New York, N.Y. : 1991). 2017, Dec; 27(12): 5635-5651.
  1. 18.   Oxime-based linker libraries as a general approach for the rapid generation and screening of multidentate inhibitors
  2. Bahta, M.; Liu, F.; Kim, S. E.; Stephen, A. G.; Fisher, R. J.; Burke, T. R.
  3. Nature Protocols. 2012, Apr; 7(4): 686-702.
  1. 19.   Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin
  2. Day, C. P.; Carter, J.; Bonomi, C.; Hollingshead, M.; Merlino, G.
  3. International Journal of Cancer. 2012, Jan; 130(1): 190-199.
  1. 20.   Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties
  2. Flynn, B. L.; Gill, G. S.; Grobelny, D. W.; Chaplin, J. H.; Paul, D.; Leske, A. F.; Lavranos, T. C.; Chalmers, D. K.; Charman, S. A.; Kostewicz, E.; Shackleford, D. M.; Morizzi, J.; Hamel, E.; Jung, M. K.; Kremmidiotis, G.
  3. Journal of Medicinal Chemistry. 2011, Sep; 54(17): 6014-6027.
  1. 21.   Inhibition of multi-drug resistant HIV-1 reverse transcriptase by nucleoside beta-triphosphates
  2. Dash, C.; Ahmadibeni, Y.; Hanley, M. J.; Pandhare, J.; Gotte, M.; Le Grice, S. F. J.; Parang, K.
  3. Bioorganic & Medicinal Chemistry Letters. 2011, Jun; 21(12): 3519-3522.
  1. 22.   A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
  2. Kelly, R. J.; Draper, D.; Chen, C. C.; Robey, R. W.; Figg, W. D.; Piekarz, R. L.; Chen, X. H.; Gardner, E. R.; Balis, F. M.; Venkatesan, A. M.; Steinberg, S. M.; Fojo, T.; Bates, S. E.
  3. Clinical Cancer Research. 2011, Feb; 17(3): 569-580.
  1. 23.   Development of thyroid gland and ultimobranchial body cyst is independent of p63
  2. Ozaki, T.; Nagashima, K.; Kusakabe, T.; Kakudo, K.; Kimura, S.
  3. Laboratory Investigation. 2011, Jan; 91(1): 138-146.
  1. 24.   Identification of Four Potential Epigenetic Modulators from the NCI Structural Diversity Library Using a Cell-Based Assay
  2. Best, A. M.; Chang, J. J.; Dull, A. B.; Beutler, J. A.; Martinez, E. D.
  3. Journal of Biomedicine and Biotechnology. 2011 11.
  1. 25.   The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
  2. Xiang, X. R.; Phung, Y.; Feng, M. Q.; Nagashima, K.; Zhang, J. L.; Broaddus, V. C.; Hassan, R.; FitzGerald, D.; Ho, M.
  3. Plos One. 2011, Jan; 6(1): 10.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel